Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 studyJonathan P. Piccini, Veronika Eder, Sead Pandzic et al.|The Lancet|2022Cited by 310
Lipoprotein-Derived Lysophosphatidic Acid Promotes Atherosclerosis by Releasing CXCL1 from the EndotheliumZhe Zhou, Andreas Schober, Pallavi Subramanian et al.|Cell Metabolism|2011Cited by 219
miR-103 promotes endothelial maladaptation by targeting lncWDR59Lucia Natarelli, Andreas Schober, Claudia Geißler et al.|Nature Communications|2018Cited by 67
MicroRNA signatures in cardiac biopsies and detection of allograft rejectionAndrea Di Francesco, Annalisa Angelini, Marny Fedrigo et al.|The Journal of Heart and Lung Transplantation|2018Cited by 44
A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injuryEla Karshovska, Andreas Schober|Journal of Thrombosis and Haemostasis|2008Cited by 43